Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain, and pruritus are managed. The Company aim to achieve this by developing new products that selectively target the body’s peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the undesirable side effects typically associated with currently available pain and itch therapeutics.

Stamford, US
Size (employees)
34 (est)
Cara Therapeutics was founded in 2004 and is headquartered in Stamford, US
Report incorrect company information

Cara Therapeutics Office Locations

Cara Therapeutics has an office in Stamford
Stamford, US (HQ)
4 Stamford Plz
Show all (1)
Report incorrect company information

Cara Therapeutics Financials and Metrics

Cara Therapeutics Financials

Market capitalization (5-Mar-2018)

391.9 m
Cara Therapeutics's current market capitalization is $391.9 m.
Show all financial metrics
Report incorrect company information

Cara Therapeutics News and Updates

Global Marijuana Market 2018 Key Players: Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings, United Cannabis, Growblox Sciences,. adds “Marijuana Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”reports to its database. Posted via Industry Today. Follow us on Twitter @IndustryToday

Major Chart Support Approaches On Cara Therapeutics (CARA)

This article is published in collaboration with Scutify, where you can find real-time markets a
Report incorrect company information